Therefore, it is suggested that TACC2 plays an oncogenic role in breast carcinoma by promotion of the cell proliferative activity, and residual carcinoma cells following surgical treatment in TACC2‐positive breast carcinomas may still have the high potential to rapidly grow and/or metastasize, despite the adjuvant therapy. This evidence concerns the gene TACC2 and breast carcinoma.